[ Price : $8.95]
Spectrum Pharmaceuticals petitions FDA asking that it not approve any ANDAs that seek to carve-out Fusilevs orphan drug exclusivit...[ Price : $8.95]
A client alert from law firm Sheppard, Mullin, Richter & Hampton hints at increased FDA scrutiny for medical devices that lend the...[ Price : $8.95]
Federal Register Notice: FDA publishes a modified list of recognized standards that it recognizes for use in premarket reviews.[ Price : $8.95]
FDA posts a Dear Healthcare Provider letter from GlaxoSmithKline informing physicians about the potential for fading over time on ...[ Price : $8.95]
FDA clears an AnthroTronix 510(k) for its computerized cognitive test battery DANA, which is intended to provide clinicians with a...[ Price : $8.95]
FDA approves a Phase 2 clinical trial protocol from Chimerix to begin clinical trials of brincidofovir in Ebola patients.[ Price : $8.95]
FDA approves new abuse deterrent labeling for Pfizers painkiller Embeda (morphine sulfate and naltrexone hydrochloride) extended-r...[ Price : $8.95]
Spectrum asks FDA to extend the approval date and orphan drug expiration date for its Fusilev to account for the delay in launch c...